SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Pfizer Reports Top-Line Results From Phase 3 Lot Consistency Study Of 20-Valent Pneumococcal Conjugate Vaccine In Pneumococcal Vaccine-Naive Adults 18-49

Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three different lots of its

Benzinga · 05/14/2020 14:00

Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three different lots of its 20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) candidate in adults 18 through 49 years of age not previously vaccinated against pneumococcal disease. Responses elicited by 20vPnC for all 20 serotypes were equivalent across all three lots, meeting the primary immunogenicity objective of the study. In this study the 20vPnC safety profile was similar to the Prevnar 13® (pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) control group. This clinical lot consistency study is expected to satisfy licensure requirements for manufacturing consistency by the U.S. Food and Drug Administration, and other countries’ regulatory agencies.

“We are excited by the progress of our adult development program for 20vPnC as this is the second phase 3 trial for this investigational vaccine for which we have positive topline data,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “These new data highlight Pfizer’s strong heritage, expertise and success in manufacturing highly-complex biological products such as pneumococcal conjugate vaccines. Demonstration of lot consistency is critical to help ensure that vaccine recipients receive the same level of protection irrespective of the manufactured lot used.”

Pfizer’s 20vPnC vaccine candidate includes 13 serotypes already included in Prevnar 13. The seven new serotypes included in 20vPnC are global causes of invasive pneumococcal disease (IPD),1,2,3,4,5 and are associated with high case-fatality rates,6,7,8,9 antibiotic resistance,5,10,11 and/or meningitis.12,13 Globally, pneumococcal pneumonia is estimated to cause about 500,000 deaths and 30 million episodes in adults 70 years and older annually. Together, the 20 serotypes included in 20vPnC are responsible for the majority of currently circulating pneumococcal disease in the U.S. and globally.14,15,16,17,18,19,20

Pfizer will seek to present and publish outcomes from this clinical trial at a future date once safety and immunogenicity data have been fully analyzed.

20vPnC Phase 3 Adult Program

Pfizer’s Phase 3 adult clinical program for 20vPnC includes three clinical trials (NCT03760146, NCT03828617, and NCT03835975) evaluating the vaccine candidate for the prevention of invasive disease and pneumococcal pneumonia in adults 18 years or older. Combined, these three trials have enrolled more than 6,000 adult subjects, including populations of vaccine-naïve adults and adults with prior pneumococcal vaccination.21,22 All three trials have been completed and the data for one remaining study will be reading out over the next few months.

  • This press release refers to NCT03828617: Phase 3 randomized, double-blind trial enrolled 1,700 adults aged 18 through 49 years with no history of pneumococcal vaccination. The study was designed to describe the safety and evaluate consistency of immune response elicited across three different lots of 20vPnC. The 20vPnC lots were three unique drug product lots. A 13vPnC arm was included in the study as a control group for safety assessments. More on the study can be found on www.clinicaltrials.gov under the identifier NCT03828617.

Additional trials include:

  • NCT03760146: Phase 3 randomized, double-blind trial comparing immune responses in patients ≥60 years old after 20vPnC administration to responses in a control group receiving 13vPnC or PPSV23. The study also evaluated immune responses of 20vPnC in adults 18 to 59 years (secondary endpoints) and described the safety profile of 20vPnC in all adults ≥18 years old (primary endpoint). Additional information about the study can be found at www.clinicaltrials.gov under the identifier NCT03760146. Pfizer announced topline findings from this trial in March 2020.
  • NCT03835975: Phase 3 randomized, open-label trial, designed to describe the safety and immune response of 20vPnC in an estimated 875 adults aged 65 years or older with prior pneumococcal vaccination. More on the study can be found on www.clinicaltrials.gov under the identifier NCT03835975.